ActoGeniX NV closed a Series B equity financing round, raising €10.7 million (US$14 million) to move its ActoBiotics program to the investigational new drug application (IND) stage in a second indication of inflammatory bowel disease (IBD). Read More
It takes a special kind of person to be able to help navigate a biotechnology company from its early stages, with all its attendant hopes and dreams into the reality of a truly therapeutic product organization, which generates revenue and builds value for its shareholders. Read More
Allecra Therapeutics GmbH, a Franco-German start-up raised €15 million (US$19.6 million) in a Series A round to take two antibiotic development programs into the clinic and through clinical proof of concept. Read More
Cancer Prevention Pharmaceuticals Inc. (CPP) is trying out its tumor-blocking approach in colon adenomas by way of a Phase III trial in a collaborative effort with the National Cancer Institute (NCI) that will enroll 1,340 survivors. Read More
• Epizyme Inc., of Cambridge, Mass., said it signed a deal with Abbott, of Abbott Park, Ill., to develop a molecular companion diagnostic test for use with EPZ-5676, its inhibitor targeting the DOT1L histone methyltransferase for the treatment of mixed lineage leukemia. Read More
• PledPharma AB, of Stockholm, said its Phase IIa MANAMI trial of mangafodipir in acute myocardial infarction is now fully recruited. The trial is assessing the safety of the PLED substance in patients undergoing coronary angioplasty. Read More
• Merck KGgA, of Darmstadt, Germany, said subsidiary EMD Serono Inc. continued expanding the firm's presence in the U.S. resulting in an estimated 20 percent increase in EMD Serono's employee base from last July to the end of 2014. Read More
